Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial
| العنوان: | Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial |
|---|---|
| المؤلفون: | Sasa Magas, Lawrence A. Leiter, David J.A. Jenkins, Elena Jovanovski, Andreea Zurbau, Lea Duvnjak, Jelena Miocic, Alexandra L Jenkins, Robert G. Josse, John L. Sievenpiper, Vladimir Vuksan |
| المصدر: | European Journal of Nutrition. 60:3071-3083 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, 030109 nutrition & dietetics, Nutrition and Dietetics, Bran, ginseng, viscous fiber, Salba-chia, glycemic management, type 2 diabetes, business.industry, Medicine (miscellaneous), 030209 endocrinology & metabolism, Type 2 diabetes, medicine.disease, law.invention, 03 medical and health sciences, Ginseng, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, medicine, Clinical endpoint, Adverse effect, business, Glycemic |
| الوصف: | Viscous dietary fiber, functional seeds and ginseng roots have individually been proposed for the management of diabetes. We explored whether their co-administration would improve glycemic control in type 2 diabetes beyond conventional therapy. In a randomized, double-blind, controlled trial conducted at two academic centers (Toronto, Canada and Zagreb, Croatia), individuals with type 2 diabetes were assigned to either an active intervention (10 g viscous fiber, 60 g white chia seeds, 1.5 g American and 0.75 g Korean red ginseng extracts), or energy and fiber-matched control (53 g oat bran, 25 g inulin, 25 g maltodextrose and 2.25 g wheat bran) intervention for 24 weeks, while on conventional standard of care. The prespecified primary endpoint was end difference at week 24 in HbA1c, following an intent-to-treat analysis adjusted for center and baseline. Between January 2016 and April 2018, 104 participants (60M:44F; mean ± SEM age 59 ± 0.8 years; BMI 29.0 ± 0.4 kg/m2; HbA1c 7.0 ± 0.6%) managed with antihyperglycemic agent(s) (n = 98) or lifestyle (n = 6), were randomized (n = 52 test; n = 52 control). At week 24, HbA1c levels were 0.27 ± 0.1% lower on test compared to control (p = 0.03). There was a tendency towards an interaction by baseline HbA1c (p = 0.07), in which a greater reduction was seen in participants with baseline HbA1c > 7% vs ≤ 7% (− 0.56 ± 0.2% vs 0.03 ± 0.2%). Diet and body weight remained unchanged. The interventions were well tolerated with no related adverse events and with high retention rate of 84%. Co-administration of selected dietary and herbal therapies was well-tolerated and may provide greater glycemic control as add-on therapy in type 2 diabetes. Registration: Clinicaltrials.gov NCT02553382 (registered on September 17, 2015). |
| تدمد: | 1436-6215 1436-6207 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099e19a8bcc695bf501a67d8e77d4644Test https://doi.org/10.1007/s00394-020-02434-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....099e19a8bcc695bf501a67d8e77d4644 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14366215 14366207 |
|---|